Predictors for the clinical benefit of anti-PD-1/PD-L1 therapy in advanced gastroesophageal cancer: a meta-analysis of clinical trials | Zendy

ZeGuo Zhuo | Zendy; HanYu Deng | Zendy; Tie-Niu Song | Zendy; GuHa Alai | Zendy; Xu Shen | Zendy; YiDan Lin | Zendy

Open Access

Predictors for the clinical benefit of anti-PD-1/PD-L1 therapy in advanced gastroesophageal cancer: a meta-analysis of clinical trials

Author(s) -

ZeGuo Zhuo,

HanYu Deng,

Tie-Niu Song,

GuHa Alai,

Xu Shen,

YiDan Lin

Publication year - 2020

Publication title -

annals of palliative medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.546

H-Index - 19

eISSN - 2224-5839

pISSN - 2224-5820

DOI - 10.21037/apm-19-430a

Subject(s) - medicine , clinical trial , cancer , meta analysis , oncology , intensive care medicine

The overall objective response rate (ORR) of published clinical trials in advanced gastroesophageal cancer patients who received anti-program-death-1 (anti-PD-1) or program-death-legend-1 (anti-PD-L1) therapy was only 10%. This ratio is far away from satisfying. It is necessary to identify patients who are more likely to benefit from the treatment. This study aimed to identify the factors with which the patients would have a higher response rate to anti-PD-1/anti-PD-L1 therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research